Stuart A. Arbuckle - 17 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, COO
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 Feb 2023
Net transactions value
-$2,022,835
Form type
4
Filing time
22 Feb 2023, 15:30:12 UTC
Previous filing
16 Feb 2023
Next filing
24 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $1,317,239 -4,498 -5.9% $292.85 71,107 17 Feb 2023 Direct
transaction VRTX Common Stock Sale $6,111 -21 -0.03% $291.01 71,086 21 Feb 2023 Direct F1
transaction VRTX Common Stock Sale $159,560 -545 -0.77% $292.77 70,541 21 Feb 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $323,114 -1,100 -1.6% $293.74 69,441 21 Feb 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $216,811 -736 -1.1% $294.58 68,705 21 Feb 2023 Direct F1, F2, F5
holding VRTX Common Stock 140 17 Feb 2023 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2 Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $292.77 (range $292.25 to $293.07).
F4 Open market sales reported on this line occurred at a weighted average price of $293.74 (range $293.30 to $294.19).
F5 Open market sales reported on this line occurred at a weighted average price of $294.58 (range $294.36 to $294.96).